Jolly Good/Teijin Pharma develop VR digital therapeutics for depression
pharmaphorum
APRIL 26, 2021
Technology firm Jolly Good and Teijin Pharma have begun a partnership to develop virtual reality digital therapeutics (VR DTx) for major depressive disorder. In 2019 Cognitant and Addenbrook’s Hospital in Cambridge, UK piloted a programme that aimed to educate patients to improve adherence to rheumatoid arthritis medicines.
Let's personalize your content